--- title: 'Research Daily Summary: What Happened on October 23, 2026' headline: Red blood cell particles boost antitumor T-cell responses in mice description: A separate microfluidic assay measured drug-combination responses in pediatric leukemia. url: https://thebench.bio/news/research/2026-10-23 topic: research date: '2026-10-23' covers: - '2026-10-23' date_published: '2026-10-23T12:03:29Z' date_modified: '2026-10-23T12:03:29Z' tags: - Industry sources: 2 publisher: TheBench.Bio --- # Research Daily Summary: What Happened on October 23, 2026 **Red blood cell particles boost antitumor T-cell responses in mice** A separate microfluidic assay measured drug-combination responses in pediatric leukemia. ## Today in brief Ultraviolet-treated red blood cell particles strengthened antitumor T-cell responses and slowed tumor growth in mouse models when paired with tumor antigens. [1] Dendritic cells carried haem from the particles to the nucleus, where it activated a pathway that supported immune-cell maturation and antigen presentation. [1] GradientScreen measured responses to drug combinations in pediatric acute lymphoblastic leukemia, including in patients who had not responded to standard treatment. [2] The assay's response measures correlated with minimal residual disease and later clinical outcomes. [2] ## Red blood cell microparticles amplify antitumor immunity in mice Microparticles generated from ultraviolet-irradiated red blood cells acted as an adjuvant, a substance that strengthens an immune response, in laboratory tests and mouse tumor models. [1] They favored T helper type 1 responses and increased tumor-specific cytotoxic T-cell activity. [1] Dendritic cells took up the particles and carried haem through lysosomes to the nucleus. [1] There, haem activated REV-ERBα, which reduced PPARγ activity and eased suppression of dendritic-cell maturation and antigen presentation. [1] In vaccination experiments, the particles paired with tumor antigens increased cytotoxic T-cell activation and reduced tumor growth, with minimal toxicity reported. [1] The findings come from preclinical work and do not establish whether the approach will work in people. [1] ## GradientScreen tests drug combinations in pediatric leukemia GradientScreen uses a microfluidic assay to test different drug ratios in pediatric acute lymphoblastic leukemia. [2] Researchers used it to measure responses in patients who had not responded to standard treatment. [2] The assay's combination-response measures correlated with minimal residual disease after treatment began and with later clinical outcomes. [2] ## Also published - [Innovation Radar: Pancreatic cancer’s metabolic weak spots](), BioCentury - [Hydrogel for sustained and localized delivery of a regulatory T cell-inducing agent promotes bone regeneration](), Nature Biomedical Engineering - [Red blood cell-derived extracellular vesicles as a potent autologous adjuvant](), Nature Biomedical Engineering - [The human microbiome and chronic disease: ten strategic priorities for research and public health](), Nature Medicine ## Sources 1. [Autologous erythrocyte microparticles drive antitumour T cell immunity via haem-mediated dendritic cell activation](), Nature Biomedical Engineering, 2026-10-23 2. [Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia](), Nature Biomedical Engineering, 2026-10-23 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: